Liver Match, a prospective observational cohort study on liver transplantation in Italy: Study design and current practice of donor-recipient matching

Digestive and Liver Disease

Volumn 43, Issue 2, 2011, Pages 155-164

  Angelico, Mario ^a   Cillo, Umberto ^a   Fagiuoli, Stefano ^a   Gasbarrini, Antonio ^a   Gavrila, Caius ^a   Marianelli, Tania ^a   Costa, Alessandro Nanni ^a   Nardi, Alessandra ^a   Strazzabosco, Mario ^a   Burra, Patrizia ^a   Agnes, Salvatore ^a   Baccarani, Umberto ^a   Calise, Fulvio ^a   Colledan, Michele ^a   Cuomo, Oreste ^a   De Carlis, Luciano ^a   Donataccio, Matteo ^a   Ettorre, Giuseppe M ^a   Gerunda, Giorgio E ^a   Gridelli, Bruno ^a   Lupo, Luigi ^a   Mazzaferro, Vincenzo ^a   Pinna, Antonio ^a   Risaliti, Andrea ^a   Salizzoni, Mauro ^a   Tisone, Giuseppe ^a   Valente, Umberto ^a   Rossi, Giorgio ^a   Rossi, Massimo ^a   Zamboni, Fausto ^a   more..

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Donor; Liver transplant; Recipient

Indexed keywords

HEPATITIS B CORE ANTIBODY;

ADOLESCENT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BRAIN DEATH; CHILD; CLINICAL PRACTICE; COLD ISCHEMIA; CROSS-SECTIONAL STUDY; DATA BASE; DONOR SELECTION; FEMALE; GRAFT RECIPIENT; HUMAN; ITALY; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; OBESITY; PRIORITY JOURNAL; SCHOOL CHILD; SEX DIFFERENCE; STUDY DESIGN; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; FIBROSIS; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HUMANS; ITALY; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SELECTION; PROSPECTIVE STUDIES; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; TREATMENT OUTCOME; WAITING LISTS;

EID: 78651467799     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2010.11.002     Document Type: Article

References (30)

1. Merion R.M., Goodrich N.P., Feng S. How can we define expanded criteria for liver donors?. J Hepatol 2006, 45:188-192.
2. Durand F., Renz J.F., Alkofer B., et al. Report of the Paris consensus meeting one expanded criteria donors in liver transplantation. Hepatology 2008, 14:1694-1707.
3. Burroughs S.G., Busuttil R.W. Optimal utilization of extended hepatic grafts. Surg Today 2009, 39:746-751.
4. Marsman W.A., Wiesner R.H., Rodriguez L., et al. Use of fatty donors is associated with diminished early patient and graft survival. Transplantation 1996, 62:1246-1251.
5. McCormack L., Petrowsky H., Jochum W., et al. Use of severely steatotic grafts in liver transplantation: a matched case-control study. Ann Surg 2007, 246:940-946.
6. Burra P., Loreno M., Russo F.P., et al. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transpl 2009, 15:619-628.
7. Tosuka E., Dodson F., Urakami A., et al. Influence of high donor serum sodium levels on early post-operative graft function in human liver transplantation: effect of correction of donor hypernatremia. Liver Transpl 1999, 5:421-428.
8. Cywinski J.B., Mascha E., Miller C., et al. Association between donor-recipient serum sodium differences and orthotopic liver transplant graft function. Liver Transpl 2008, 14:59-65.
9. Feng S., Goodrich N.P., Bragg-Gresham J.L., et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006, 6:783-790.
10. Segev D.L., Maley W.R., Simpkins C.E., et al. Minimizing risk associated with elderly liver donors by matching to preferred recipients. Hepatology 2007, 46:1907-1918.
11. Maluf D.G., Edwards E.B., Kauffman H.M. Utilization of extended criteria donor liver allograft: is the elevated risk of failure independent of the Model for End-Stage Liver Disease score of the recipient?. Transplantation 2006, 82:1653-1657.
12. Volk M.L., Lok A.S.F., Pelletier S.J., et al. Impact of the Model for End-Stage Liver Disease allocation policy on the use of high-risk organs for liver transplantation. Gastroenterology 2008, 135:1568-1574.
13. Schaubel D.E., Sima C.S., Goodrich N.P., et al. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008, 419-425.
14. Feng S. Increased donor risk: who should bear the burden?. Liver Transpl 2009, 15:570-573.
15. Stroffolini T., Almasio P.L., Sagnelli E., et al. Evolving landscape of chronic hepatitis B: a multicenter Italian study. J Med Virol 2009, 1999-2006.
16. Marsman W.A., Wiesner R.H., Rodriguez L., et al. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1996, 62:1246-1251.
17. Sagnelli E., Stroffolini T., Mele A., et al. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J Med Virol 2005, 75:522-527.
18. El-Sarag H.B., Davila J.A., Petersen N.J., et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003, 139:817-823.
19. Thuluvath P.J., Guidinger M.K., Fung J.J., et al. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010, 10:1003-1019.
20. Sharma P., Harper A.M., Hernandez J.L., et al. Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation. Am J Transplant 2006, 6:1957-1962.
21. Piscaglia F., Camaggi V., Ravaioli M., et al. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the Model for End-Stage Liver Disease system. Liver Transpl 2007, 13:857-866.
22. De Giorgio M., Vezzoli S., Cohen E., et al. Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria. Liver Transpl 2010, 16:503-512.
23. Merion R.M., Schaubel D.E., Dykstra D.M., et al. The survival benefit of liver transplantation. Am J Transplant 2005, 5:307-313.
24. Heuman D.M., Abou-Assi S.G., Habib A., et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk of early death. Hepatology 2004, 40:802-810.
25. Gotthard D., Weiss K.H., Baumgartner M., et al. Limitations of the MELD score in predicting mortality or need for removal from waiting list in patients awaiting liver transplantation. BMC Gastroenterol 2009, 9:72.
26. Marino I. Are we ready to match donor and recipient in liver transplantation?. Liver Transpl 2006, 12:1574-1576.
27. Yu L., Koepseil T., Manhart L., Ioannou G. Survival after orthotopic liver transplantation: the impact of antibody against hepatitis B core antigen in the donor. Liver Transpl 2009, 15:1343-1350.
28. Cholongitas E., Papatheodoridis G.V., Burroughs A.K. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 2010, 52:272-279.
29. Sharma P., Balan V., Hernandez J.L., et al. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl 2004, 10:36-41.
30. Pomfret E., Washbum K., Wald C., et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010, 16:262-278.